ADG126

Phase 2Small molecule

Sanofi

ADG126 is one of 123 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Liver CancersActive, not recruiting

Colorectal CancerRecruiting

Advanced/metastatic Solid TumorsRecruiting

Solid TumorPhase 1

Recruiting

Advanced Liver CancersPreclinical

Active, not recruiting

Colorectal CancerPhase 2

Recruiting

Advanced/metastatic Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

ADG126

Sanofi

Phase 2

2 2

Nubeqa

Bayer

Preclinical

2 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 8

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 9

Carboplatin AUC-5

Merck & Co.

Preclinical

1 10

Soc

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Advanced/metastatic Solid Tumors

NCT05405595

Q3 2027

PreclinicalActive, not recruiting

Advanced Liver Cancers

NCT04524871

Q4 2027

Phase 2Recruiting

Colorectal Cancer

NCT06846268

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT05584670

Clinical

Trials by Indication[1]

Solid Tumor2 trials

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05836324·570 enrolled

A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors

Recruiting· Sanofi logo

Sanofi·Preclinical·NCT05584670·542 enrolled

Colorectal Cancer1 trial

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06846268·20 enrolled

Advanced/Metastatic Solid Tumors1 trial

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Recruiting·AAdagene Inc·Phase 1/2·NCT05405595·186 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ADG126. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ADG126 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ADG126. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

ADG126

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Solid Tumor2 trials

Colorectal Cancer1 trial

Advanced/Metastatic Solid Tumors1 trial

Advanced Liver Cancers1 trial

References

Drug Info

Quick Facts

Related News